Improvement of Idiopathic Pyoderma Gangrenosum During Treatment With Anti-Tumor Necrosis Factor Alfa Monoclonal Antibody

Abstract

Pyoderma gangrenosum (PG) is an inflammatory ulcerative condition of unknown etiology. An autoimmune mechanism including immune complex—mediated neutrophilic vascular reactions has been suggested. The role of tumor necrosis factor (TNF) in PG remains unclear. Evidence supports the idea that TNF plays a role in chronic inflammation and migration of neutrophils to these lesions. PG is frequently associated with various diseases, but up to 50% of cases are idiopathic. There are several reports describing the successful use of infliximab™ (Remicade ®, Centocor, Inc, Horsham, Pa), a chimeric antitumor necrosis factor α monoclonal antibody, in the treatment of inflammatory bowel disease— associated PG, but there have been few reported cases of infliximab in the treatment of idiopathic PG. The authors present a dramatic improvement in 4 cases of idiopathic PG of the lower leg treated with infliximab.

Keywords

pyoderma gangrenosum infliximab™leg ulcers anti-TNF alfa

Get full access to this article

View all access options for this article.

References

Chakrabarty A. , Phillips T. Leg ulcers of unusual causes. Int J Lower Extremity Wounds 2003;2(4):207-16.

Choucair MM , Fivenson DP Pyoderma gangrenosum: a review of the disease and treatment options. Wounds 2001;13(3):119-22.

Burns T. , Breathnach S. , Cox N. , Griffiths C. Pyoderma gangrenosum. In: Blackwell Science , editor. Rook's text book of dermatology. Oxford (UK): Blackwell Science; 2005. p. 49.36-49.39.

Reichrath J. , Bens G. , Bonowitz A. , Tilgen W. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients . J Am Acad Dermatol 2005;53(2):273-83.

Livideanu C. , Lpsker D. , Paul C. , Juillard J. , Schubert B. Pyoderma gangrenosum as initial manifestation of Graves'disease. Clin Exp Dermatol 2006;31(5);659-61.

Provost TT Pyoderma gangrenosum. Adv Stud Med 2003;3: 116-18.

Wolff K. , Stingl G. Pyoderma gangrenosum. In: Freedberg IM , Eisen AZ , Wolff K , Austen FK , editors. Fitzpatrick's dermatology in general medicine. 5th ed. New York: McGraw-Hill; 1999. p. 1140-6.

Powell FC , Su WP , Perry HQ Pyoderma gangrenosum: classification and management. J Am Acad Dermatol 1996;34: 395-409.

Jorizzo JL , Solomon AR , Zanolli MD , Leshin B. Neutrophilic vascular reactions. J Am Acad Dermatol 1988;19:983-1005.

10.

Hurwittz RM , Haseman JH The evolution of pyoderma gangrenosum: a clinicopathologic correlation. Am J Dermapathol 1993;15:28-33.

11.

Powell FC , Schroeter AL , Su WP , Perry HO Pyoderma gangrenosum: a review of 86 patients. Q J Med 1985;55:173-86.

12.

Rustin MH , Gilkes JJ , Robinson TW Pyoderma gangrenosum associated with Behcet's disease: treatment with thalidomide . J Am Acad Dermatol 1990;23:941-4.

13.

Green SM , Kerdel FA , Falabella AF , Kirsner R. Infliximab: a treatment option for ulcerative pyoderma gangrenosum. Wounds 2003;15(2):49-53.

14.

McGowan JW

4th, Johnson CA, Lynn A. Treatment of pyoderma gangrenosum with etanercept. J Drugs

Dermatol 2004;3(4):441-4.

15.

Hubbard VG , Friedmann AC , Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol 2005;152:1059-61.

16.

Mouser JF , Hyams JS Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease. Clin Ther 1999;21:932-42.

17.

Old LJ Tumor necrosis factor (TNF). Sci Am 1988;258:59-60, 69-75.

18.

Van Deventer SJH. Tumor necrosis factor and Crohn's disease . Gut 1997;40:443-8.

19.

Mouser JF , Hyams JS Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease. Clin Ther 1999;21:932-42.

20.

Kaur MR , Lewis HM Severe recalcitrant pyoderma gangrenosum treated with infliximab. Br J Dermatol 2005;153: 689-91.